Division of Cell Biology, Department of Biology, Science Faculty, Utrecht University, Padualaan 8, 3584 CH, Utrecht, The Netherlands.
Breast Cancer Res Treat. 2013 Jul;140(2):263-72. doi: 10.1007/s10549-013-2635-6. Epub 2013 Jul 17.
Ductal carcinoma in situ (DCIS) of the breast is difficult to remove completely during surgery as it is not palpable and can therefore require re-excision. Real-time visualization of DCIS using near-infrared fluorescent probes could help the surgeon during surgery as well as the pathologist post-operatively to distinguish the tumor from healthy tissue. As hypoxia-induced necrosis is a common phenomenon in DCIS, we investigated the molecular imaging of DCIS using a fluorescent antibody targeting a hypoxia marker, carbonic anhydrase IX (CAIX), in a preclinical mouse model. A monoclonal antibody against human CAIX was fluorescently labeled with the near-infrared dye IRDye800CW and characterized in vitro. An in vivo study was performed in SCID/Beige mice that were orthotopically transplanted with human breast cancer cells mimicking human DCIS (MCF10DCIS) and MCF10DCIS stably expressing CAIX. A clinically approved fluorescence imaging system was used to monitor probe uptake and to determine tumor-to-normal tissue ratios (TNR). Mean in vivo TNR of CAIX-transduced (CAIX+) tumors was 7.5 ± 0.5. Mean in vivo TNR of DCIS tumors with hypoxic areas reached a plateau level at 48 h after injection of 2.1 ± 0.1 (mean ± SEM) compared to 1.7 ± 0.1 in DCIS without hypoxic areas. Mean intra-operative TNR of DCIS tumors with necrotic regions was higher than that of DCIS tumors without necrotic regions 96 h after injection-2.9 ± 0.1 and 1.5 ± 0.1, respectively-while the TNR of CAIX+ tumors was 11.2 ± 1.0. Specific tumor uptake of MabCAIX-IRDye800CW was confirmed by a biodistribution assay, and immunofluorescence imaging on tumor sections showed specific uptake in hypoxic tumor regions, with higher contrast than conventional chromagen-based immunohistochemistry. Molecular fluorescence imaging with MabCAIX-IRDye800CW can be successfully used to detect hypoxic DCIS before and during surgery to facilitate radical resection. Furthermore, it allows for sensitive CAIX-specific immunofluorescence microscopy of tumor sections, thereby introducing the concept of molecular fluorescence pathology.
乳腺导管原位癌(DCIS)在手术中难以完全切除,因为它不可触及,因此可能需要再次切除。使用近红外荧光探针实时可视化 DCIS 可以帮助外科医生在手术中以及病理学家在手术后将肿瘤与健康组织区分开来。由于缺氧诱导的坏死是 DCIS 中的常见现象,我们使用针对缺氧标志物碳酸酐酶 IX(CAIX)的荧光抗体在临床前小鼠模型中研究了 DCIS 的分子成像。针对人 CAIX 的单克隆抗体用近红外染料 IRDye800CW 进行荧光标记,并在体外进行了表征。在 SCID/Beige 小鼠中进行了一项体内研究,这些小鼠被原位移植了模拟人类 DCIS(MCF10DCIS)的人类乳腺癌细胞和稳定表达 CAIX 的 MCF10DCIS。使用临床批准的荧光成像系统来监测探针摄取并确定肿瘤与正常组织的比值(TNR)。CAIX 转导(CAIX+)肿瘤的平均体内 TNR 为 7.5 ± 0.5。与无缺氧区域的 DCIS 肿瘤相比,缺氧区域的 DCIS 肿瘤在注射后 48 小时达到平台水平,平均体内 TNR 为 48 小时达到平台水平,为 2.1 ± 0.1(平均值 ± SEM),而无缺氧区域的 DCIS 肿瘤为 1.7 ± 0.1。注射后 96 小时,有坏死区域的 DCIS 肿瘤的平均术中 TNR 高于无坏死区域的 DCIS 肿瘤-分别为 2.9 ± 0.1 和 1.5 ± 0.1-而 CAIX+肿瘤的 TNR 为 11.2 ± 1.0。MabCAIX-IRDye800CW 的生物分布测定证实了特异性肿瘤摄取,肿瘤切片的免疫荧光成像显示缺氧肿瘤区域的摄取特异性更高,与传统基于显色的免疫组织化学相比对比度更高。使用 MabCAIX-IRDye800CW 的分子荧光成像可成功用于术前和术中检测缺氧性 DCIS,以促进根治性切除。此外,它允许对肿瘤切片进行敏感的 CAIX 特异性免疫荧光显微镜检查,从而引入分子荧光病理学的概念。